Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bleomycin
Drug ID BADD_D00280
Description A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Indications and Usage For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Marketing Status approved; investigational
ATC Code L01DC01
DrugBank ID DB00290
KEGG ID D07535
MeSH ID D001761
PubChem ID 5460769
TTD Drug ID D06UVD
NDC Product Code 0143-9241; 69097-364; 0703-3155; 0143-9240; 16714-908; 61703-332; 61703-323; 16714-886; 0409-0332; 70121-1567; 0409-0323; 0703-3154
UNII 40S1VHN69B
Synonyms Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina
Chemical Information
Molecular Formula C55H84N17O21S3+
CAS Registry Number 11056-06-7
SMILES CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O) OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6 =NC(=CS6)C(=O)NCCC[S+](C)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Phlebitis12.02.01.002; 24.12.03.004--
Pleuritic pain22.12.01.007--
Pneumonia11.01.09.003; 22.07.01.003---
Pneumonitis22.01.01.006--
Pruritus23.03.12.001--
Pulmonary fibrosis22.01.02.006--
Pyrexia08.05.02.003--
Radiation pneumonitis12.05.02.002; 22.01.04.001---
Rales22.12.01.011---
Rash23.03.13.001---
Raynaud's phenomenon24.04.03.003---
Scleroderma10.04.07.001; 15.06.01.002; 23.03.02.005---
Skin exfoliation23.03.07.003---
Skin hyperpigmentation23.05.01.003--
Skin hypertrophy23.01.04.002---
Skin striae23.01.05.002---
Stomatitis07.05.06.005--
Tenderness08.01.08.005---
Thrombocytopenia01.08.01.002---
Thrombotic microangiopathy01.01.02.006; 20.01.07.004; 24.01.01.013---
Tumour pain16.32.03.003--
Ulcer08.03.06.001---
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Musculoskeletal discomfort15.03.04.001---
Metaplasia08.03.04.004---
Haemorrhage24.07.01.002---
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene